These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 7018819)

  • 21. [Patient preference for oral chemotherapy].
    Schöffski P
    Krankenpfl J; 2002; 40(1-2):40-1. PubMed ID: 12035416
    [No Abstract]   [Full Text] [Related]  

  • 22. [A cooperative late phase II trial of l-leucovorin and 5-fluorouracil in the treatment of advanced gastric cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)].
    Takeda S; Taguchi T; Ohta J; Kurihara M; Abe T; Ohtani T; Yonemura Y; Ohno T; Hirabayashi N; Nakano S
    Gan To Kagaku Ryoho; 1995 Jun; 22(7):903-10. PubMed ID: 7793996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A double-blind randomized comparative study of oral 5-fluorouracil (5-FU), cyclophosphamide (CPA), and 5-FU + CPA in advanced breast cancer].
    Takayama T; Nomura Y
    Gan To Kagaku Ryoho; 2000 Jan; 27(1):73-80. PubMed ID: 10660736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial.
    Hidalgo M; Hornedo J; Lumbreras C; Trigo JM; Colomer R; Perea S; Gómez C; Ruiz A; García-Carbonero R; Cortés-Funes H
    Cancer; 1999 Jan; 85(1):213-9. PubMed ID: 9921995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Continuous double administration of 5 fluorouracil (intravenous and intraperitoneal) modulated by folinic acid: phase I clinical study and pharmacokinetics in patients with intra-abdominal developing cancers].
    de Forni M; Gualano V; Canal P; Martel P; Izar-Soum F; Chevreau C; Soulié P; Roché H; Bugat R
    Bull Cancer; 1993 May; 80(5):408-17. PubMed ID: 8173194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Slow intravenous perfusion of 5-flourouracil. Clinical results].
    Huys J; Van Vaerenbergh PM; Dewulf L
    Presse Med (1893); 1966 Jun; 74(28):1461-5. PubMed ID: 5939775
    [No Abstract]   [Full Text] [Related]  

  • 27. Substitution of oral fluoropyrimidines for infusional fluorouracil with radiotherapy: how much data do we need?
    Crane CH; Sargent DJ
    J Clin Oncol; 2004 Aug; 22(15):2978-81. PubMed ID: 15210736
    [No Abstract]   [Full Text] [Related]  

  • 28. Randomized trial comparing weekly bolus 5-fluorouracil plus leucovorin versus monthly 5-day 5-fluorouracil plus leucovorin in metastatic colorectal cancer.
    Wang WS; Lin JK; Chiou TJ; Liu JH; Fan FS; Yen CC; Lin TC; Jiang JK; Yang SH; Chen PM
    Hepatogastroenterology; 2000; 47(36):1599-603. PubMed ID: 11149011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical pharmacology of oral and intravenous 5-fluorouracil (NSC-19893).
    Cohen JL; Irwin LE; Marshall GJ; Darvey H; Bateman JR
    Cancer Chemother Rep; 1974; 58(5 Pt 1):723-31. PubMed ID: 4609602
    [No Abstract]   [Full Text] [Related]  

  • 30. [5-fluorouracil effectiveness and toxicity in the treatment of digestive trac.t neoplasms as a function of the mode of administration].
    Zelechowska JA; Madej G
    Nowotwory; 1976; 26(1):29-36. PubMed ID: 1257062
    [No Abstract]   [Full Text] [Related]  

  • 31. Administration of 5-fluorouracil by hypodermoclysis.
    Lemon HM; Foley JF; Miller DM
    Nebr Med J; 1973 Jan; 58(1):4-6. PubMed ID: 4682787
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical studies with tubercidin administered by direct intravenous injection.
    Bisel HF; Ansfield FJ; Mason JH; Wilson WL
    Cancer Res; 1970 Jan; 30(1):76-8. PubMed ID: 4917978
    [No Abstract]   [Full Text] [Related]  

  • 33. [Variant angina in peroral treatment with 5-fluorouracil].
    Denison H; Himmelmann A
    Lakartidningen; 1988 May; 85(19):1705. PubMed ID: 3374200
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical evaluation of anticancer alkylating agent, carboquone (NSG-134679).
    Himori T; Wakui A; Saito T
    Sci Rep Res Inst Tohoku Univ Med; 1983 Dec; 30(1-4):92-9. PubMed ID: 6678502
    [No Abstract]   [Full Text] [Related]  

  • 35. [Studies on the metabolic fate of 5-fluorouracil in the oral administration].
    Anada H; Nakamura N; Marumo H
    Yakugaku Zasshi; 1974 Sep; 94(9):1131-8. PubMed ID: 4476782
    [No Abstract]   [Full Text] [Related]  

  • 36. EST 1668--effect of high-dose glucose on therapy with 5-fluorouracil.
    Hall TC; Schotz W; Shnider BI; Taylor S
    Med Pediatr Oncol; 1978; 5(1):15-31. PubMed ID: 370533
    [No Abstract]   [Full Text] [Related]  

  • 37. [Experimental clinical observations of the effect and excretion of Sandoscill].
    Tabeau J; Bobrowski A; Kudla A; Gabryś B
    Med Welt; 1970 Aug; 33():1416-9. PubMed ID: 5517791
    [No Abstract]   [Full Text] [Related]  

  • 38. Thioproline.
    Gosálvez M
    Lancet; 1980 Mar; 1(8168 Pt 1):597. PubMed ID: 6102316
    [No Abstract]   [Full Text] [Related]  

  • 39. Time and vehicle studies of a safe and effective method for administration of 5-fluorouracil.
    Hall TC; Cavins JA; Khung CL; Griffiths CT; Dederick MM; Yount WJ
    Cancer; 1966 Jul; 19(7):1008-12. PubMed ID: 5939300
    [No Abstract]   [Full Text] [Related]  

  • 40. Assessment of the role of randomized clinical trials in establishing treatment policies.
    Garnier HS; Flamant R; Fohanno C
    Control Clin Trials; 1982 Sep; 3(3):227-34. PubMed ID: 7151440
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.